BCL2L1 and hematologic disorder: In contrast to hematological malignancies, where GCs may reduce Bcl-xL expression thereby favoring apoptosis (Laane et al. 2007), in PCa it was shown that GCs upregulate Bcl-xL resulting in resistance to apoptosis-inducers (Petrella et al. 2006).